Pharmacology conferences| Pharmacology 2023| Pharma events 20223 | Pharma conferences | Europe | USA | Middle East

Theme: Addressing the Demand in Pharmacology and Drug Design Proficiency

Pharmacology 2023

Scientific Program

Renowned Speakers

Lihua Sun
Harbin Medical University
China

Susan Welsh
Chief Safety Officer Sanofi
USA

Teresa Duda
Salus University
USA

Aline Diogo Marinho
Federal University of Ceara
Brazil

Jiyoung Kim
Seoul National University
South Korea

Marcel Gubler
F. Hoffmann-La Roche
Switzerland

Susanne Bremer-Hoffmann
Directorate F â€“ Health, European Commission
Germany

Young Hyo Kim
Inha University College of Medicine
Spain

Hari Shanker Sharma
Uppsala University
Sweden

Stefano Bonassi
IRCCS San Raffaele Pisana
Italy

Vivian SW Chan Fung
SafeWork NSW
Australia

Giovanni Pagano
Federico II Naples University
Canada

Berit Smestad Paulsen
University of Oslo
Norway

Yukio Yoneda
Kanazawa University
Japan

Gerd Bode
University of Gottingen
Germany

Belamy B Cheung
Lowy Cancer Research Centre
Australia

Jean-Marc Lemaitre
IRMB
France

Eva Cecilie Bonefeld-JÃ¸rgensen
University of Aarhus
Denmark

Alan Poole
ECETOC
Belgium

Emmanuel O. Akala
Howard University
USA

Bimal Roy Krishna
Touro University
USA

Pharmacology 2023

Conference Series invites all the participants across the globe to attend 36^thWorld Congress on Pharmacology Scheduled during July 25-26, 2023 Amsterdam, Netherlands. Which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Pharmacology 2023 focuses on the importance to understand drugs and how they can affect human physiology. It is with better understanding of Pharmacology one can know the right dosage and dosage forms of drugs. More research in pharmacology deals with identifying and responding to drug interactions and its side effects along with its mechanism of action, its therapeutic index and thereby treat accordingly. More intensive study with the interaction between drug and its therapeutic effect helps to identify the properties of ideal drugs.

Why to attend???

Join your peers around the world focused on learning about Pharmacology and related advances, which is your single best opportunity to reach the largest assemblage of participants from the Pharmacology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Pharmacology are hallmarks of this conference.

Target Audience:

Students, Scientists, Researchers, and Faculty of Pharmaceutical Universities
Medical Colleges, Researchers from Pharmaceutical Companies, Pharmacy Associations and Societies
Business Entrepreneurs, Training Institutes, Software developing companies
Manufacturing Medical Devices Companies, CRO and Data Management Companies.

Young Scientist Benefits:

Our conferences provide best Platform for your research through oral presentations.
Share the ideas with both eminent researchers and mentors.
Young Scientist Award reorganization certificate and memento to the winners
Young Scientists will get appropriate and timely information by this Forum.
Platform for collaboration among young researchers for better development
Award should motivate participants to strive to realize their full potential which could in turn be beneficial to the field as whole.

Track 01: Pharmacology

Pharmacology is a branch in science concerned with the effects of the drugs on living organisms (pharmacodynamics) and the effects of living organisms with the drugs (pharmacokinetics). This subject embodies drug composition and properties, interactions, toxicology, therapy, and medicinal uses such as application and antipathogenic capabilities. Pharmacology is subdivided into two categories as mentioned above, pharmacodynamics and pharmacokinetics. Pharmacodynamics deals with chemical interactions with body/cell receptors. Pharmacokinetics, on the other hand, deals with the four stages of chemicals passing through the body: absorption, distribution, metabolism and excretion.

Related Societies:

Societies in USA: American Association of Pharmaceutical Scientists, American Association of Pharmacy Technicians, American College of Clinical Pharmacology, American College of Clinical Pharmacy (ACCP), American Institute of the History of Pharmacy.

Societies in Europe: European Federation for Pharmaceutical Sciences (EUFEPS), Italian Society for Pharmaceutical Sciences (SISF), Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFC), European Behavioural Pharmacology Society (EBPS), Belgian Society of Pharmaceutical Sciences

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 02: Neuro Pharmacology

Neuropharmacology is the study of how drugs affect cellular function in the nervous system, and the neural mechanisms through which they influence behaviour. There are two main branches of neuropharmacology: behavioural and molecular. Behavioural neuropharmacology focuses on the study of how drugs affect human behaviour (neuropsychopharmacology), including the study of how drug dependence and addiction affect the human brain. Molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with the overall goal of developing drugs that have beneficial effects on neurological function. Both of these fields are closely connected, since both are concerned with the interactions of neurotransmitters, neuropeptides neuro hormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Studying these interactions, researchers are developing drugs to treat many different neurological disorders, including pain, neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, psychological disorders, addiction, and many others.

Related Societies:

Societies in USA: American Association of Pharmaceutical Scientists, American Association of Pharmacy Technicians , American College of Clinical Pharmacology, American College of Clinical Pharmacy (ACCP), American Institute of the History of Pharmacy

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 03: Toxicology

Toxicology is the scientific study of adverse effects that occur in living organisms due to chemicals. It involves observing and reporting symptoms, mechanisms, detection and treatments of toxic substances, in particular relation to the poisoning of humans.

It includes environmental agents and chemical compounds found in nature, as well as pharmaceutical compounds that are synthesized for medical use by humans. These substances may produce toxic effects in living organisms including disturbance in growth patterns, discomfort, disease and death.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 04: Forensic Toxicology

Forensic Toxicology is the use of toxicology and other is disciplines such as analytical chemistry, pharmacology and clinical chemistry to aid medical or legal investigation of death, poisoning, and drug use. The primary concern for forensic toxicology is not the legal outcome of the toxicological investigation or the technology utilized, but rather the obtainment and interpretation of results. A toxicological analysis can be done to various kinds of samples. A forensic toxicologist must consider the context of an investigation, in particular any physical symptoms recorded, and any evidence collected at a crime scene that may narrow the search, such as pill bottles, powders, trace residue, and any available chemicals. Provided with this information and samples with which to work, the forensic toxicologist must determine which toxic substances are present, in what concentrations, and the probable effect of those chemicals on the person.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 05: Molecular and Clinical Pharmacology

The Department of Molecular and Clinical Pharmacology is dedicated to define disease processes, understanding both drug actions and adverse reactions, developing novel therapeutic strategies for intervention and optimizing the benefit–risk ratio of current and new drugs. We are based within the Institute of Translational Medicine, whose overall aim is to take basic scientific understanding and translate it into innovations for the benefit of patients, the public and health systems across the world.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 06: Pharmacovigilance Significance and Scope

Concept of Pharmacovigilance and its Significance enhances the impact of pharmacovigilance on patient welfare and public health and to know what is Pharmacovigilance. This track gives a brief discussion on Pharmacovigilance role in healthcare system. Pharmacovigilance legislation gives an outlook on the rules and laws to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of pharmacovigilance system is very crucial to maintain the safety data, Detection and Evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines.

Related Journals:

Related Associations or Societies:

Societies in USA: International Society of Pharmacovigilance | Drug Safety & Pharmacovigilance | Association of Clinical Research Professionals (ACRP) | American Association of Pharmaceutical Scientists | Association of British Pharmaceutical Industry | the Society of Clinical Research Associates (SOCRA) | Society for Clinical Trials (SCT) | Canadian Association of Professionals in Regulatory Affairs | Clinical Research Society (CRS)

Societies in Europe: European Association for Clinical Pharmacology (EACPT) | International Society of Pharmacovigilance (ISOP) | European Medicines Agency, Pharmaceutical Information and Pharmacovigilance Association (PIPA) | Association of CROs Czech Republic (ACRO-CZ) | European Clinical Research Infrastructures Network (ECRIN) | European Society for Clinical Investigation (ESCI).

Societies in Asia and Pacific: Society of Pharmacovigilance, International Society of Pharmacovigilance: (ISOP) | Indian Society for Clinical Organization Research (ISCR) | Indian Society for Clinical Research | Clinical Trials Society | Society for Clinical Trials Association of Clinical Research | The Society of Clinical Research Associates | Association of Clinical Research Organization | Clinical Research Society | Indian Council of Medical Research (ICMR) | Japan CRO Association (JCROA) | Pan-Asian Clinical Research Association (PACRA) | Central Society for Clinical and Translational Research (CSCTR)

Track 07: Recent Advances in Pharmacology and Toxicology

The pharmaceutical and Toxicological industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured based on findings from the study of life sciences. Clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 08: Pre-clinical and Clinical Trails

In drug development, preclinical development, also named preclinical studies and nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data are collected.

The main goals of pre-clinical studies are to determine the safe dose for first-in-man study and assess a product's safety profile. Products may include new medical devices, drugs, gene therapy solutions and diagnostic tools. On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.

Societies in USA: American Association of Pharmaceutical Scientists, American Association of Pharmacy Technicians, American College of Clinical Pharmacology, American College of Clinial Pharmacy (ACCP), American Institute of the History of Pharmacy

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 09: Cardio Vascular Pharmacology

Cardiovascular Pharmacology deals with the study of the effects of drugs upon the heart or circulatory system. It mainly contributes to the safety profile of potential new drugs and provides pharmacological data that can be used for optimization of further compounds and the ultimate selection of compounds suitable for clinical development. The cardiac drugs affect the function of the heart in three main ways. They can affect the force of contraction of the heart muscle (inotropic effects), they can affect the frequency of the heart beat or heart rate (chronotropic effects) or they can affect the regularity of the heart beat (rhythmic effects). Drugs can also affect blood vessels by altering the state of compression of the smooth muscle in the vessel wall, altering its diameter and accordingly directing the volume of blood stream. Such medications are classified as vasoconstrictors or vasodilators depending on the smooth muscle lining contraction and relaxation respectively.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 10: Ecopharmacovigilance

In a context of severe pharmaceutical pollution, “Ecopharmacovigilance” (EPV) has been an area of novel interest. It aims to ensure that significant environmental issues associated with pharmaceuticals in the environment are identified in a timely way, and managed appropriately. EPV has become a research hotspot as a comprehensive and boundary science in Europe and North America, and regulatory requirements governing the comprehensive environmental risk assessment (ERA) of pharmaceuticals exist in these regions. A speedy Chinese pharmaceutical industry development and drug consumption, China should shoulder more international responsibility and contribute to the worldwide EPV. Compared to the west, EPV in China is in its infancy. We analyzed the current state of EPV-related practice in China and found that many efforts have been made by the Chinese government and specialists to control the ever-worsening environmental pharmaceutical pollution problems, including consummating related policies and regulations, revealing the occurrence and behavior of pharmaceutical residues in environment and developing new technologies to improve their removal performance.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 11: Drug Safety Testing

Drug safety testing is happening in a growing number of countries including Austria, Canada, Colombia, Mexico, the Netherlands, Switzerland, United States and the UK. This briefing discusses testing using sophisticated analytical equipment, not DIY kits that cannot identify many contaminants, or strength. Drug safety testing is happening in a growing number of countries including Austria, Canada, Colombia, Mexico, the Netherlands, Switzerland, United States and the UK. This briefing discusses testing using sophisticated analytical equipment, not DIY kits that cannot identify many contaminants, or strength.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 12: ImmunoPharmacology

Immunopharmacology and Immunotoxicology is a bimonthly peer-reviewed medical journal that covers preclinical and clinical studies on the regulatory effects of various agents on immunocompetent cells, as well as the immunotoxicity exerted by xenobiotics and drugs. Hence, the journal encompasses a broad range of pathologies (e.g. acute and chronic infections, allergy, autoimmunity, cancer, degenerative disorders, inflammation, and primary and secondary immunodeficiencies). It is published by Informa

Track 13: Ocular Pharmacology

Ophthalmic diseases include both those analogous to systemic diseases (eg, inflammation, infection, neuronal degeneration) and not analogous (eg, cataract, myopia). Many anterior segment diseases are treated pharmacologically through eye drops, which have an implied therapeutic index of local therapy. Unlike oral dosage forms administered for systemic diseases, eyedrops require patients not only to adhere to treatment, but to be able to accurately perform-ie, instill drops correctly. Anatomical and physiological barriers make topical delivery to the anterior chamber challenging-in some cases more challenging than absorption through the skin, nasal passages, or gut. Treatment of the posterior segment (eg, vitreous, retina, choroid, and optic nerve) is more challenging due to additional barriers. Recently, intravitreal injections have become a standard of care with biologics for the treatment of macular degeneration and other diseases. Although the eye has esterases, hydroxylases, and transporters, it has relatively little CYP450 enzymes. Because it is challenging to obtain drug concentrations at the target site, ocular clinical pharmacokinetics, and thus pharmacokinetic-pharmacodynamic interactions, are rarely available. Ophthalmic pharmaceuticals require consideration of solubility, physiological pH, and osmolarity, as well as sterility and stability, which in turn requires optimal pharmaceutics. Although applied locally, ocular medications may be absorbed systemically, which results in morbidity and mortality (eg, systemic hypotension, bronchospasm, and bradycardia)

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 14: Clinical Pharmacy and Pharmacotherapeutics

Clinical pharmacy is the discipline of Pharmacy where pharmacists are meant to provide patient care which helps in optimizing the use of drugs and improves health, wellness, and prevents diseases. This session is dealt with topics like basic components of clinical pharmacy practice Prescribing drugs, Reviewing drug use, Administering drugs, Counseling, Documenting professional services, Consulting, Preventing Medication Errors etc.,

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 15: Drug Screening and Discovery

All pharmaceutical researchers know the feeling. Somewhere out there must be that elusive molecule — one that will inhibit this enzyme or activate that receptor in the way they want, and without causing unwanted side-effects. But finding it is another matter. For small-molecule drugs — the mainstay of the pharmaceutical industry — time-consuming and expensive screening is needed to pick out promising candidates from the vast number of natural and synthetic compounds available. Testing large numbers of compounds to see if they produce an appropriate biochemical or cellular effect is usually one of the first steps in the drug-discovery pathway, and ways of making this screening faster, more effective and less expensive are in continual development.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 16: Safety Pharmacology

Safety pharmacology evaluations are an essential step in assessing acute and potentially life-threatening risks of novel pharmaceuticals as part of an IND-enabling program. Second-tier safety pharmacology studies can be used to determine mechanistic effects on vital functions and evaluate potential adverse effects on organ systems such as renal and gastrointestinal systems.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 17: Clinical Research Statistics

Statistical analysis is one of the foundations of evidence-based clinical practice, a key in conducting new clinical research and in evaluating and applying prior research. In this paper, we review the choice of statistical procedures, analyses of the associations among variables and techniques used when the clinical processes being examined are still in process. We discuss methods for building predictive models in clinical situations, and ways to assess the stability of these models and other quantitative conclusions. Techniques for comparing independent events are distinguished from those used with events in a causal chain or otherwise linked. Attention then turns to study design, to the determination of the sample size needed to make a given comparison, and to statistically negative studies.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 18: Adverse Drug Reactions

Adverse drug reactions can be considered a form of toxicity; however, toxicity is most commonly applied to effects of overingestion (accidental or intentional) or to elevated blood levels or enhanced drug effects that occur during appropriate use (eg, when drug metabolism is temporarily inhibited by a disorder or another drug). For information on toxicity of specific drugs see the table Symptoms and Treatment of Specific Poisons. Side effect is an imprecise term often used to refer to a drug’s unintended effects that occur within the therapeutic range.

Because all drugs have the potential for adverse drug reactions, risk-benefit analysis (analyzing the likelihood of benefit vs risk of ADRs) is necessary whenever a drug is prescribed.

In the US, 3 to 7% of all hospitalizations are due to adverse drug reactions. ADRs occur during 10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe. These statistics do not include the number of ADRs that occur in ambulatory and nursing home patients. Although the exact number of ADRs is not certain, ADRs represent a significant public health problem that is, for the most part, preventable.

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

Track 19: Bio Chemical Pharmacology

Biochemical pharmacology uses the methods of biochemistry, biophysics, molecular biology, structural biology, cell biology, and cell physiology to define the mechanisms of drug action and how drugs influence the organism by studies on intact animals, organs, cells, subcellular compartments and individual protein molecules. The biochemical pharmacologist also uses drugs as probes to discover new information about biosynthetic and cell signalling pathways and their kinetics, and investigates how drugs can correct the biochemical abnormalities that are responsible for human illness, thus enabling the elucidation of pathophysiological mechanisms that pave the way for further drug discover

Related Societies:

Societies in Asia: The Pharmaceutical Society of Australia, Kuwait Pharmaceutical Association, Maryland Pharmacists Association, Turkish Pharmacists Association, Utah Pharmaceutical Association

The pharmaceutical industry comprises of companies that are engaged in research, development, manufacture and distribution drugs for human or veterinary use. The primary function of the research-based pharmaceutical corporations is to create value by discovering and producing effective medicines, vaccines and services that improve patients’ well-being, and can be sold in markets at a profit. As well as increasing shareholder value, this contributes significantly to the quality and protection of life and helps make the world a better place. In the past 60 years, innovation and technology have driven huge improvements in global health.

Every clinical trial in Austria has to be approved by the Federal Office for Safety in Healthcare and needs a positive opinion of the ethics committee. Details on terminological definitions and on the requirements and implementation of clinical trials are set out in the Medicinal Products Act in § 2a and § 28 to § 48. The objective is to prove the effectiveness and tolerability of these forms of treatment and to improve the medical care of future patients. In principle, a distinction is made between clinical trials (intervention studies) and non-interventional studies.

Market Analysis of Global Pharmaceutical Industries

The global $1.12 trillion market in 2023, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2023. Generics sales will increase from $73 billion in 2015 to $115 billion in 2023, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.

The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.

The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.

The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval.15 U.S generic drug sales reached an estimated $70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favouring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and monetary crisis.

According to the Quintiles IMS Institute predicts that the pharmaceutical market by 2021 will reach nearly USD 1,485 billion, by an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. Global brand spending is forecast to increase to USD 815-832 billion in 2021. Global generic spending is expected to increase to USD 495-505 billion by 2021.

The United States share of global spending will increase from USD 461.7 billion in 2016 to USD 645-675 billion in 2021, while the European share of spending will grow from USD 151.8 billion to USD 170-200 billion. Meanwhile, pharmerging countries will spend nearly 315-345 USD billion in 2021 from 242.9 in 2016.

Major Pharmacology Associations around the Globe

Glance at Market of Pharmacology:

These data describe the outcome of the patient as defined in U.S. reporting regulations. Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life threatening. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	July 25-26, 2023
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1
Poster Opportunity Closed	Click Here to View